Fetuin-A level in type 2 diabetic patients: relation to microvascular complications

Abstract

Background Fetuin-A is a hepatic secretory protein that binds to insulin receptors and inhibits insulin resistance (IR) kinase activity as well as IR autophosphorylation in vivo and in vitro. Aim This study aimed to investigate fetuin-A levels in patients with type 2 diabetes mellitus (T2DM) and their relation to microvascular complications. Patients and methods This descriptive study was conducted on 160 patients. Group 1 included (n=40) diabetic patients without microvascular complications, group 2 (n=40) included diabetic patients with nephropathy, group 3 (n=40) included diabetic patients with retinopathy, and group 4 represented (n=40) healthy control. Serum fetuin-A and insulin were measured by enzyme-linked immunosorbent assay. Glucose was measured, and homeostasis model assessment for IR (HOMA-IR) was estimated. Results Fetuin-A levels were significantly higher in all T2DM groups compared with controls. There was a significant positive correlation between fetuin-A, insulin, and HOMA-IR in all studied groups. There was a significant positive correlation between fetuin-A and some of metabolic syndrome criteria in all diabetic patients. There were high significant increases in the mean levels of fetuin-A, insulin, and HOMA-IR in the diabetic patients with nephropathy group than other groups. There was a nonsignificant increase in fetuin-A levels in diabetic patients with retinopathy than the diabetics without microvascular complications. Conclusion Fetuin-A may be used as a marker for microvascular complications in T2DM, especially the diabetic nephropathy. Antifetuin drugs may be invented to delay diabetic microvascular complications.

Evaluation of Fetuin-A level in diabetic retinopathy

“…The goal of this study was to determine the Fetuin-A level as a marker that may help in the early diagnosis of DR. We observed a highly significant difference in FBG, 2HPP, and HbA1c between the studied groups (p< 0.001). This was in agreement with Al-Said et al [7], who found a significant difference in the mean levels of FBG in the diabetic without complications group versus the DR group. But in contrast to our study, Al-Said et al [7] concluded that there were no significant differences were detected in the mean levels of 2HPP between the diabetic without complications group and the DR group.…”

“…This was in agreement with Al-Said et al [7], who found a significant difference in the mean levels of FBG in the diabetic without complications group versus the DR group. But in contrast to our study, Al-Said et al [7] concluded that there were no significant differences were detected in the mean levels of 2HPP between the diabetic without complications group and the DR group. This may be attributed to the poor glycemic control and lifestyle changes of the studied patients.…”

“…On the other hand, our study observed that there were no significant differences between the three studied groups regarding Fetuin-A. Our results coincided with Al-Said et al [7], who showed that there was a nonsignificant increase in the mean levels of Fetuin-A in patients with DR compared with diabetic patients without micro-vascular complications. On the other hand, serum Fetuin-A levels showed no significant difference between patients with T2DM and controls [5].…”

Fetuin A levels and its correlation with lipid profile in type 2 diabetes mellitus patients

“…This may project to increase 134 million by 2045. 1,2 Due to its complex pathophysiology, several biomarkers have been studied for identifying its vascular complications. However, many of these biomarkers were related to inflammation, metabolic or procoagulant.…”

Evaluation of Vimentin and Some Biochemical Parameters in the Blood of Acute Myocardial Infarction Patients

“…Schmid glycoprotein) is 55-59 kDa an endogenous a 55-59 kDa phosphorylated glycoprotein which produced predominantly in the hepatocytes and secreted into serum [8], play a key role in the safety from vascular calcification by solubilizing calcium and phosphorus in serum [9], is an antiinflammatory glycoprotein declined during systemic inflammatory process that is to say it is a negative acute phase reactant. Lp(a) is a Lipoprotein that contains similar to low density lipoprotein (LDL) apolipoprotein B and in addition apolipoprotein(a) which is attached by a disulfide bridge [10].…”